Unexpected uterine sarcomas after hysterectomy and myomectomy for presumed leiomyoma: a retrospective study of 26,643 patients
暂无分享,去创建一个
[1] Lu-Wen Wang,et al. Proportion of Uterine Malignant Tumors in Patients with Laparoscopic Myomectomy: A National Multicenter Study in China , 2017, Chinese medical journal.
[2] W. C. Ang,et al. Incidence of Malignancy and Myoma Variants at Surgery for Presumed Benign Symptomatic Myomas. , 2017, Journal of minimally invasive gynecology.
[3] B. Seagle,et al. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. , 2017, Gynecologic oncology.
[4] K. Pavlakis,et al. Morcellating uterine mesenchymal tumors: The pathologist's view , 2017, The journal of obstetrics and gynaecology research.
[5] K. Nawapun,et al. Undiagnosed Uterine Sarcomas Identified During Surgery for Presumed Leiomyoma at a National Tertiary Hospital in Thailand: A 10-Year Review , 2017, International Journal of Gynecologic Cancer.
[6] T. Pawlik,et al. Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival: A Multi-Institution Analysis From the US Extrahepatic Biliary Malignancy Consortium , 2017, JAMA surgery.
[7] N. Fleming,et al. Uterine Adenosarcoma: a Review , 2016, Current Oncology Reports.
[8] Young Tae Kim,et al. Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease , 2016, BMC Cancer.
[9] B. Rueda,et al. The Epidemiology and Genetics of Uterine Leiomyoma. , 2016, Best practice & research. Clinical obstetrics & gynaecology.
[10] P. G. Paul,et al. Uterine Sarcomas in Patients Undergoing Surgery for Presumed Leiomyomas: 10 Years' Experience. , 2016, Journal of minimally invasive gynecology.
[11] T. Raine-Bennett,et al. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation , 2016, Obstetrics and gynecology.
[12] D. Richardson,et al. Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications , 2015, Obstetrics and gynecology.
[13] J. Lang,et al. Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation , 2015, International Journal of Gynecologic Cancer.
[14] Q. Yang,et al. Incidence and clinical characteristics of unexpected uterine sarcoma after hysterectomy and myomectomy for uterine fibroids: a retrospective study of 10,248 cases , 2015, OncoTargets and therapy.
[15] M. Pascual,et al. Impact of Surgery on the Evolution of Uterine Sarcomas. , 2015, Journal of minimally invasive gynecology.
[16] S. Blank,et al. Uterine carcinosarcoma: A review of the literature. , 2015, Gynecologic oncology.
[17] J. Kennedy,et al. Uterine sarcomas and parasitic myomas after laparoscopic hysterectomy with power morcellation. , 2015, American journal of obstetrics and gynecology.
[18] M. Lieng,et al. Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women. , 2015, Journal of minimally invasive gynecology.
[19] S. As-Sanie,et al. Unexpected Gynecologic Malignancy Diagnosed After Hysterectomy Performed for Benign Indications , 2015, Obstetrics and gynecology.
[20] Kathryn H Schmitz,et al. Quality of Life, Body Mass Index, and Physical Activity Among Uterine Cancer Patients , 2014, International Journal of Gynecologic Cancer.
[21] Yuan Gao,et al. Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007. , 2014, International journal of clinical and experimental pathology.
[22] B. Quade,et al. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. , 2014, Gynecologic oncology.
[23] J. Segars,et al. The estimated annual cost of uterine leiomyomata in the United States. , 2012, American journal of obstetrics and gynecology.
[24] Sun-Kyung Park,et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. , 2011, Gynecologic oncology.
[25] M. Rijn,et al. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. , 2011, Gynecologic oncology.
[26] D. Baird,et al. New Directions in the Epidemiology of Uterine Fibroids , 2010, Seminars in reproductive medicine.
[27] J. Prat,et al. Uterine sarcomas: a review. , 2010, Gynecologic Oncology.
[28] J. Prat. FIGO staging for uterine sarcomas , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[29] J. Nesland,et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients , 2009, Histopathology.
[30] C. Walker,et al. Uterine Fibroids: The Elephant in the Room , 2005, Science.
[31] B. Mellado,et al. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. , 2002, International journal of radiation oncology, biology, physics.
[32] P. Freitag. [Uterine sarcomas]. , 1997, Ceska gynekologie.
[33] M. K. Hardiman. Routine hysterectomy for large asymptomatic uterine leiomyomata: a reappraisal. , 1992, Obstetrics and gynecology.
[34] Z. Petrovich,et al. Treatment of uterine sarcomas , 1990, Cancer.